A 15-minute microwave procedure known as Swift is providing a potential new path for treating stubborn plantar warts by triggering the body's immune response. while early success rates are high, medical experts suggest that more rigorous testing is needed before the treatment becomes a standard NHS service.
Targeting HPV through controlled microwave heat
The Swift procedure, which arrived in Britain in 2016, represents a significant shift in how podiatrists approach human papillomavirus (HPV) infections. Rather than using traditional methods like cryotherapy to freeze tissue or salicylic acid to dissolve skin, this method uses a handheld probe to deliver brief bursts of microwave energy just millimeters beneath the skin.. As the source reports, this heat is intended to stimulate the immune system, encouraging it to recognize and attack the infected cells rather than simply destroying the visible wart.
This approach is particularly relevant for plantar warts, which are often caused by HPV entering through small breaks in the skin in communal areas like swimming pools or public showers. for many patients, these verrucas are not just a cosmetic issue but a source of significant physical discomfort, often described as feeling like walking on a small, sharp object due to the pressure of the foot.
The 90 percent success rate in early clinical data
Early clinical observations suggest that the Swift treatment is highly effective for long-term sufferers. The report indicates that approximately 77 percent of verrucas clear within three to six months, with success rates climbing to nearly 90 percent after nine months of follow-up.
One specific case highlighted in the report involves an elderly woman from Essex named Jane, who successfully cleared a verruca that had persisted for over 50 years. This level of success is a major draw for clinicians who treat patients with recurrent or particularly stubborn lesions that have failed to respond to other therapies like needling or laser treatment.
The £120 to £200 price tag for private care
Access to this technology remains a significant hurdle for many patients in the United Kingdom. because Swift is not yet a standard NHS treatment, many individuals must seek the procedure through private podiatry clinics.
According to the report, individual sessions typically cost between £120 and £200. Furthermore, while manufacturers suggest that an average of three treatments may suffice, some podiatrists report that many patients require closer to six sessions, spaced roughly one month apart to allow the immune response to develop.
The missing evidence from large-scale independent trials
The primary obstacle to widespread medical adoption is the current lack of large-scale, independent clinical trials. While early studies are encouraging, many clinicians remain cautious about labeling Swift as a guaranteed first-line treatment without more comparative data directly testing it against established methods.
There are several unanswered questions regarding how Swift performs against surgical removal or cryotherapy in a controlled, large-scale setting. Additionally, because the source focuses on encouraging early studies,it remains unverified how the treatment performs across a broader, more divese demographic of patients with varying immune responses or underlying health conditions.
Comments 0